相关实验视频

Updated: Jul 15, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

在非小细胞肺癌中,BATF2抑制PD-L1表达并调节CD8+T细胞透

Junwei Liu¹, Jie Li², Zhan Tuo³

¹Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

The Journal of biological chemistry

|September 30, 2023

概括

该研究发现,BATF2抑制了编程死亡配体1,改善了肺癌的免疫治疗反应. BATF2表达可以预测诊断,预后和治疗疗效.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

免疫检查点抑制剂 (ICI) 在癌症治疗中表现有前途,但反应率有很大差异.
迫切需要免疫疗法耐药性机制和可靠的预测生物标志物,特别是肺癌.

研究的目的:

研究BATF2在调节免疫检查点连接体表达中的作用及其对抗瘤免疫力的影响.
确定BATF2作为预测非小细胞肺癌 (NSCLC) 免疫治疗疗效的潜在生物标志物.

主要方法:

使用BATF2淘汰和人类异种移植小鼠模型的体内研究.
通过RT定量PCR和西式涂抹对RNA和蛋白质表达的分析.
对患者数据的生物信息分析,以将BATF2表达与免疫反应相关联.

主要成果:

在患者血中,BATF2的表达与被编程死亡配体1 (PD-L1) 水平呈负相关性.
BATF2通过抑制涉及ZEB2.2的PI3K-AKT通路来抑制PD-L1表达.
在NSCLC中,BATF2通过增强CD8+T细胞透和激活来促进抗瘤免疫力.

结论:

在调节瘤免疫微环境和克服免疫疗法耐药性方面,BATF2起着至关重要的作用.
在循环瘤细胞和组织中BATF2表达是预测NSCLC诊断,预后和免疫治疗反应的有希望的生物标志物.

关键词:

最常见的BATF2方法在PD-L1中.在ZEB2中,它是ZEB2.免疫疗法免疫疗法肺癌是一种肺癌.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...